Den overordnede incidens og profil af virus -, bakterie - og svampe- infektioner blandt patienter, der blev behandlet med basiliximab eller placebo i kombination med to- stofs - og tre- stofs immunosuppressiv behandling var sammenlignelig mellem grupperne.
The overall incidence and profile of viral, bacterial and fungal infections among patients treated with basiliximab or placebo in combination with dual and triple immunosuppressive therapy was comparable between the groups.